Open an account

Petros Pharmaceuticals

PTPI · NASDAQ

$0.0028−$0.0001 (−3.45%)TodayMarket closed ·
Prev close $0.0029

About PTPI

Petros Pharmaceuticals, Inc. engages in men's health therapeutics. The company is headquartered in New York City, New York and currently employs 3 full-time employees. The company went IPO on 2020-12-02. The firm is engaged in developing a software-as-a-service (SaaS) platform designed to assist pharmaceutical companies in meeting FDA standards to assist in the Rx-to-OTC switch. In addition to the SaaS component, the platform is intended to incorporate software as a medical device (SaMD) capabilities, transforming traditional OTC medications into digitally enabled solutions. The SaMD interface seeks to be designed as customized and branded to pharmaceutical therapy and established as a specific application pathway to that therapy. Together, it aims to develop the SaaS and SaMD components to create a scalable, licensable platform that supports various classes of medications across the pharmaceutical industry, assisting pharmaceutical companies achieve regulatory approval, while delivering consumer-focused healthcare solutions.

Employees
3
Headquarters
New York City, New York
Listed
Dec 2, 2020
Sector
Health Care
Industry
Pharmaceuticals
Website
petrospharma.com

PTPI key statistics

Market cap
120.76K
Price-earnings ratio
0.10
Dividend yield
—
Average volume
143.66K
Volume
2
Open price
$0.0027
High today
$0.003
Low today
$0.0027
52 Week high
$0.024
52 Week low
$0.0017

Petros Pharmaceuticals (PTPI) at a glance

Petros Pharmaceuticals (PTPI) last traded at $0.0028, with a market cap of 120.76K and a price-to-earnings ratio of 0.10.

Today the stock has traded between $0.0027 and $0.003. The current price is 3.7% above the day's low and 6.7% below its high.

Volume so far is 2 shares, below the average of 143.66K shares a day.

Over the past year Petros Pharmaceuticals has ranged from $0.0017 to $0.024, and now sits 5% of the way up that range.

Petros Pharmaceuticals met or beat analyst EPS estimates in 1 of the last 4 quarters. In Q3 FY24 it reported -$13.25 per share against an estimate of -$7.39.

PTPI earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 4 quarters, by 52.9% on average.

  1. Q4 FY23: reported -$57.25 per share against an estimate of -$28.31
  2. Q1 FY24: reported -$42.25 per share against an estimate of -$36.72
  3. Q2 FY24: reported -$9.25 per share against an estimate of -$19.64
  4. Q3 FY24: reported -$13.25 per share against an estimate of -$7.39

PTPI news

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Avi Kapoor

    Why Toll Brothers Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Avi Kapoor

    US Stocks Mixed; Coca-Cola Posts Upbeat Earnings

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

Similar companies

Companies in the same industry as Petros Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.